Cited by

• Computational drug repurposing: approaches, evaluation of in silico resources and case studies.

  Tanoli Z, Fernández-Torras A, Özcan UO, Kushnir A, Nader KM, Gadiya Y, Fiorenza L, Ianevski A, Vähä-Koskela M, Miihkinen M, Seemab U, Leinonen H, Seashore-Ludlow B, Tampere M, Kalman A, Ballante F, Benfenati E, Saunders G, Potdar S, Gómez García I, García-Serna R, Talarico C, Beccari AR, Schaal W, Polo A, Costantini S, Cabri E, Jacobs M, Saarela J, Budillon A, Spjuth O, Östling P, Xhaard H, Quintana J, Mestres J, Gribbon P, Ussi AE, Lo DC, de Kort M, Wennerberg K, Fratelli M, Carreras-Puigvert J, Aittokallio T. Tanoli Z, et al. Nat Rev Drug Discov. 2025 Jul;24(7):521-542. doi: 10.1038/s41573-025-01164-x. Epub 2025 Mar 18. Nat Rev Drug Discov. 2025. PMID: 40102635 Review.
• Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.

  Pichler AS, Amador C, Fujimoto A, Takeuchi K, de Jong D, Iqbal J, Staber PB. Pichler AS, et al. Histopathology. 2025 Jan;86(1):119-133. doi: 10.1111/his.15376. Histopathology. 2025. PMID: 39679758 Free PMC article. Review.
• Establishing predictive machine learning models for drug responses in patient derived cell culture.

  Abdel-Rehim A, Orhobor O, Griffiths G, Soldatova L, King RD. Abdel-Rehim A, et al. NPJ Precis Oncol. 2025 Jun 13;9(1):180. doi: 10.1038/s41698-025-00937-2. NPJ Precis Oncol. 2025. PMID: 40514399 Free PMC article.
• Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.

  Nössing C, Herek P, Shariat SF, Berger W, Englinger B. Nössing C, et al. Curr Opin Urol. 2024 Jul 1;34(4):251-257. doi: 10.1097/MOU.0000000000001177. Epub 2024 Apr 10. Curr Opin Urol. 2024. PMID: 38602053 Free PMC article. Review.